Spectrofluorimetric Determination of Silodosin Using NBD-Cl Reagent: Applications to Capsules and Content Uniformity...

Area of Science:

• Analytical Chemistry
• Pharmaceutical Analysis

Background:

• Silodosin (SDN) is clinically approved for benign prostatic hyperplasia symptoms.
• Accurate quantification of SDN is crucial for therapeutic efficacy and quality control.

Purpose of the Study:

• To develop and validate a novel, affordable spectrofluorimetric method for silodosin quantification.
• To establish a robust analytical strategy suitable for pharmaceutical and clinical settings.

Main Methods:

• Utilized 4-chloro-7-nitrobenzofurazan (NBD-Cl) as a fluorogenic reagent to react with silodosin (SDN).
• Optimized reaction conditions (pH, temperature, NBD-Cl concentration) for maximal fluorescence emission.
• Validated the method according to International Council for Harmonisation (ICH) guidelines.

Main Results:

• Achieved high linearity (R² > 0.999) over a concentration range of 40-750 ng/mL.
• Demonstrated excellent accuracy (98.92-101.67% recovery) and precision (RSD < 2%).
• Successfully applied the method for silodosin quantification in pharmaceutical capsules with good content uniformity.

Conclusions:

• The developed spectrofluorimetric method is simple, reproducible, and cost-effective.
• This validated approach avoids complex instrumentation, making it suitable for pharmacokinetic research and quality control.
• The technique offers a promising alternative for accurate silodosin analysis in complex matrices.